Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.39 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063920 | 0.93 | SHBG (0.43) | SHBGALOX5ESR2ESR1MEN1 | |
| SCHEMBL28694041 | 0.91 | SHBG (0.48) | SHBGALOX5ESR2ESR1HMGB1 | |
| SCHEMBL4055487 | 0.88 | ALOX5 (0.54) | SHBGALOX5MEN1MAPTKMT2A | |
| SCHEMBL31181945 | 0.85 | SHBG (0.56) | SHBGALOX5ESR2ESR1HMGB1 | |
| SCHEMBL30374543 | 0.85 | SHBG (0.56) | SHBGALOX5ESR2ESR1HMGB1 | |
| SCHEMBL3177884 | 0.85 | SHBG (0.56) | SHBGALOX5ESR2ESR1HMGB1 | |
| SCHEMBL13609036 | 0.84 | CA1 (0.45) | SHBGESR2ESR1AMY1AHSD17B1 | |
| SCHEMBL69172 | 0.83 | ESR2 (0.49) | ALOX5ESR2ESR1HSD17B1 | |
| SCHEMBL4062078 | 0.83 | ALOX5 (0.49) | SHBGALOX5MEN1MAPTKMT2A | |
| SCHEMBL3710965 | 0.82 | SHBG (0.61) | SHBGALOX5ESR2ESR1HMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | SHBG 3960/4885ALOX5 576/4885ESR2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.